Pfizer (NYSE:PFE) has announced its vaccine candidate promises to be 90% effective in protecting against COVID-19 infections.
The announcement included the interim analysis results of its Phase 3 trial. Pfizer had earlier suggested that it would announce those results in late October.
The promising data clears the way for Pfizer to apply for emergency-use authorization from FDA for the vaccine, which it developed in collaboration with the German firm BioNTech.
Get the full story from our sister site, Drug Discovery & Development.